Vertex Pharmaceuticals Incorporated (VRTX) CEO Dr. Reshma Kewalramani on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22
This Stock Is Trouncing the Market in 2022 -- and Its Prospects Just Got Even BetterThe Motley Fool • 05/05/22
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 DiabetesBusiness Wire • 05/02/22
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del MutationBusiness Wire • 04/20/22